SK Biopharmaceuticals advances into the Greater China market via a CNS focused Chinese company with China’s 6 Dimensions Capital, backed by a large series A financing. It has also licensed its CNS therapy pipeline to the new Chinese operation.

Two SK Group affiliates benefit from COVID-19 vaccine manufacturing activities and US sales of novel drugs, while other factors such as a recovery in prescription sales, new launches and falling milestone payments affected results at other traditional South Korean pharma firms in the second quarter.

The Phase III clinical trial showed a noticeable placebo effect compared with OV101.

A Phase II trial of the CH24H inhibitor showed a statistically significant benefit in children with the rare epilepsy syndrome Dravet Syndrome, but not in Lennox-Gastaut syndrome (LGS).